Kılınç, DeryaJafar, VugarAyan, OrhanÇevik, Mehmet UğurAslanhan, HamzaDündar, AhmetYılmaz, Ahmet2024-05-192024-05-1920232980-1915https://doi.org/10.17944/interdiscip.1285784https://search.trdizin.gov.tr/yayin/detay/1180625https://hdl.handle.net/20.500.12713/4034Objective: Epilepsy is a neurological disease characterized by recurrent seizures. The underlying pathophysiological mechanisms in epilepsy are not fully known. Our aim is to investigate the relationship between serum adipocytokine and interleukin (IL)-18 levels in epilepsy patients receiving and not receiving antiepileptic therapy. Method: Our study was established as three groups. I: Epilepsy patients receiving antiepileptic therapy (n=30), II: Newly diagnosed epilepsy patients (n=30) and III: Control group (n=30). Serum adipocytokine and IL-18 levels were measured by enzyme-linked immunoassorbent assay method. Results: It was determined that serum adipocytokine and IL-18 levels were increased in epilepsy patients who received topiramate treatment and did not receive antiepileptic therapy compared to the control group. Serum glucose, total protein, cholesterol and albumin concentrations of patients who received antiepileptic treatment were decreased compared to the control group (p0.05). It was found that the body mass index (BMI) ratio of epilepsy patients who received antiepileptic treatment decreased and was significant compared to the control group and the group that did not receive treatment (peninfo:eu-repo/semantics/openAccessArticle1448182410.17944/interdiscip.12857841180625